Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. …………… Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O’Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators. N Engl J Med. 2020 Jan 1. PubMed

Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Installed Polymeric Nanocarrier.

Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Installed Polymeric Nanocarrier. …………… Min HS, Kim HJ, Naito M, Ogura S, Toh K, Hayashi K, Kim BS, Fukushima S, Anraku Y, Miyata K, Kataoka K. Angew Chem Int Ed Engl. 2020 Jan 29. PubMed

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. …………… Østergaard ME, De Hoyos CL, Wan WB, Shen W, Low A, Berdeja A, Vasquez G, Murray S, Migawa MT, Liang XH, Swayze EE, Crooke ST, Seth PP. Nucleic Acids Res. 2020 Jan 25. PubMed